The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo
in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN)
after a 16-week treatment period.
Details
Treatment
Placebo,
Nemolizumab
Clinical Study Identifier
NCT04501679
Sponsor
Galderma R&D
Last Modified on
16 January 2021
How clear was the trial content above?
Hard
Easy
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
Enable functional cookies in order to access shared annotations.